Abstract
SANO, R., FUJINO, A., SAITO, T., TAKENAKA, K., YAHATA, K., OGYU, A. and TOYOTA, T. Reduction by Niceritrol Treatment of Serum Lipoprotein(a) in Normolipidemic Patients with Coronary Artery Disease. Tohoku J. Exp. Med., 1993, 169 (4), 299-307-The effect of niceritrol at an ordinary dose (1500mg/ day) on the serum lipoprotein(a) (Lp(a)) concentration was investigated in 25 normolipidemic patients with coronary artery disease. The serum Lp(a) level was reduced by approximately 21% after 3 months of treatment (before treatment, 30.3±4.1mg/100ml; during treatment, 22.6±2.4mg/100ml; p<0.01). By one month after the drug was discontinued, the Lp(a) returned to a pretreatment level (30.8±2.8mg/100ml). The levels of LDL-cholesterol and apoB were decreased significantly by the drug therapy; LDL-cholesterol increased closely to a pretreatment level after withdrawal of the drug. The percentage reduction of Lp(a) was significantly correlated with that of fibrinogen (r=0.763, p<0.01). Plasma concentration of fibrinogen was decreased in the patients whose reduction rate of Lp(a) was 30% or more. These results indicate that niceritrol has Lp(a)-lowering effect; sufficient reduction of Lp(a) may improve dyscoagulopathy of patients with coronary artery disease.-coronary artery disease; normolipidemia; lipoprotein(a); plasminogen activator inhibitor-1; fibrinogen; Niceritrol
